Summary
Introduction: Lenalidomide is an immunomodulatory derivative of thalidomide with significantly greater in vitro activity and a different toxicity profile. In preclinical trials it has shown synergy with chemotherapy.
Patients and methods: Primary objective of this study was to determine the maximum tolerated doses of docetaxel and carboplatin when combined with oral lenalidomide in a standard phase I study design. Between September 2004 and May 2005, 14 patients with pathologically proven solid tumors, ≤2 prior chemotherapy regimens, performance status ECOG 0/1, and adequate organ function were enrolled. Dose limiting toxicities (DLT) were defined as ≥ grade 3 non-hematological, or grade 4 hematological toxicity. No growth factors were used during cycle 1.
Results: Three of four patients treated at dose level 1, docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, and lenalidomide 10 mg orally daily on Days 1–14 of a 21 day cycle experienced DLT (grade 3 electrolyte changes in two patients, and grade 4 neutropenia in one patient). Ten patients were treated at dose level −1, docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, and lenalidomide 5 mg orally daily on Days 1–14 of a 21 day cycle with one DLT (Grade 4 neutropenia). There were no treatment-related deaths or irreversible toxicities. Of the 14 response-evaluable patients, five achieved a partial response (5 out of 9 patients with non-small cell lung cancer.
Conclusions: Docetaxel 60 mg/m2 and carboplatin AUC 6 on Day 1, with lenalidomide 5 mg orally daily on Days 1–14 days of a 21 day cycle is the maximum tolerated dose without the use of prophylactic growth factors. This combination is active and further evaluation in a phase II trial is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bartlett JB, Michael A, Clarke IA et al (2004) Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90(5):955–961
Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210–216
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100(9):3063–3067
Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380–386
List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352(6):549–557
Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050–4053
Schafer PH, Gandhi AK, Loveland MA et al (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305(3):1222–1232
Dredge K, Dalgleish AG, Marriott JB (2002) Recent developments in antiangiogenic therapy. Expert Opin Biol Ther 2(8):953–966
Payvandi F, Wu L, Haley M et al (2004) Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230(2):81–88
Haslett PA, Klausner JD, Makonkawkeyoon S et al (1999) Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 15(13):1169–1179
Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9(11):1625–1630
Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4(4):314–322
Haslett PA, Hanekom WA, Muller G, Kaplan G (2003) Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 187(6):946–955
Thiele A, Thormann M, Hofmann HJ, Naumann WW, Eger K, Hauschildt S (2000) A possible role of N-cadherin in thalidomide teratogenicity. Life Sci 67(4):457–461
Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31(2–3):213–221
Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96(9):2943–2950
Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99(12):4525–4530
Sandler Aea (2005) Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. In: ASCO annual meeting; 2005.
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
Belani CPHY, Ramnathan R et al (1997) Docetaxel and carboplatin: A phase ! and pharmacokinetic trial for advanced non-hematological malignancies. In: ASCO
Giannakakis TKS, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V (2002) A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res 22(6B):3743–3748
Belani CP, Einzig A, Bonomi P et al (2000) Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 11(6):673–678
Hussein MA MAK, Brand C, Pearce GL, Reed J, Bruening K, Sartori P, Srkalovic G, Olesnyckyj M, Knight R, Balinski K, Zeldis J (2003) Doxil (D), Vincristine (V), reduced frequency Dexamethasone (d) and Revlimid(R) (DVd-R) a phase I/II trial in advanced relapsed/refractory multiple myeloma (Rmm) patients. Session type: Oral session. Blood 63a–64a:abstract 208
Marsh L, Khan M, Needle M, Amato R (2006) Phase II study of lenalidomide in pts with metastatic renal cell cancer. Abstract 4533. In: ASCO
Choueiri T, Dreicer R, Rini B, Elson P, Garcia J, Mekhail T, Bukowski R (2006) Phase II study of lenalidomide in pts with metastatic renal cell carcinoma. Abstract 4539. In: ASCO
Papdopoulos K, Mendelson D, Preston G, Lopez A, Ricart A, Schwartz G, Needle M, Gordon M (2005) A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors. In: AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics
Author information
Authors and Affiliations
Additional information
Revlimid® is a registered trademark of Celgene Corporation.
Rights and permissions
About this article
Cite this article
Kalmadi, S., Davis, M., Dowlati, A. et al. Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors. Invest New Drugs 25, 211–216 (2007). https://doi.org/10.1007/s10637-006-9025-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-006-9025-4